Sentences with phrase «demanding over a new contract»

There have been reports that Liverpool are keen to secure his signature in the summer, as well as rumours that he has had a bust - up with Arsene Wenger, and that he has become demanding over a new contract, but the England international isn't happy with the speculation — claiming the rumours to be nothing but «nonsense».

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

The Crown corporation said Monday that CUPW's demands are «not affordable» and would add $ 1 billion in costs over the life of a new contract.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Although many will suggest that Robson has a personal vendetta of sorts aimed squarely at the Grinch who stole soccer, that doesn't make his words any less truthful... such tactics are nothing new... in the U.S.this business practice has become so common that even the players regularly use the media to manipulate public opinion (LeBron James did likewise to rally public support for himself and away from his teammate, Kyrie Irving, who has asked to be traded)... whether for contract leverage or to rally support for or against certain players, this strategy can be incredibly effective at times, but when it misses the mark it can be dangerously divisive... for a close - to - the - vest team like Arsenal to use such nefarious means to manufacture a wedge between the fans and it's best player (again), is absolutely despicable... for the sanctimonious higher - ups who demand that it's players adhere to a certain protocol regarding information deemed «in house» or else to intentionally spread «fake» news or to provide certain outlets with privileged information for such purposes is pretty low indeed... no moral high ground here, just a big club pretending to be a small club so that they can continue to pull the wool over the eyes of a dedicated, albeit somewhat naive, fan base... so not only does this club no give a shit about it's fans, this clearly shows that clubs primary interests aren't even soccer related... for all intent and purposes Kroenke doesn't care if we're a soccer club or a tampon factory as long as we continue to maximized his investment... stay woke people... great to see more and more people commenting on the state of the franchise... this club needs to be held accountable for it's actions

Arsene Wenger did not come out and completely confirm the recent Arsenal transfer rumours about the big wage demands of the club's two biggest names Alexis Sanchez and Mesut Ozil, with both the German and the Chilean currently in talks over new contracts with the club, but he did seem to suggest in an Evening Standard report that they were likely to be getting more money and being the best paid Arsenal players if they do sign new deals.

If this were Wilshere scoring these goals and winning us trophies Arsenal fans would be all over this demanding a new contract, but Ramsey has never seemed to be liked, mainly because he hasn't always lived up to it, but he's done a far better job that most of the players in our squad and has saved the manager blushes on multiple occasions.

The Belgium international is in disagreement over a new contract with Spurs, who are unwilling to meet his # 150,000 - a-week wage demands and have not included him in their squad recently.

Further, it's claimed that Barca will struggle to satisfy his demands as after already signing Neymar and Luis Suarez to new contracts, they are at risk of falling foul of La Liga's salary restrictions which ensure clubs aren't allowed to spend over 70 percent of their income on wages.

I believe there is one thing affecting players performance and that is uncertainty... and there are 3 culprits here... ozil and sanchez for holding the club to ransom over their pay demands for a new contract and wenger for not asserting control over the matter.

Sanchez — gone Ozil — 90 % gone and honestly not worth the weekly wages he's demanding Jack W — last year of contract and no definitive discussions on new deal Santi — his Arsenal career due to injuries is over Boss — Sadly his best years are behind him Walcott — bench warmer that isn't good enough to feature weekly in the EPL Ramsey — contract winding down and he consistently isn't good enough for Arsenal Welbeck — see Ramsey Giroud — Frenchmen needs and deserves 1st team football ahead of this summer's WC.

When i remember that Theo freaking Walcott held Monsiuer Wenger over ransom with demands of playing as center forward in exchange of signing a new contract and Wenger obliged!

At the beginning of the month, the Mirror reported that, despite having three years remaining on his current contract, the France international was offered a new deal — although his wage demands saw negotiations over an extension break down.

After months of negotiations with Liverpool over a new contract, Emre Can has set his demands at # 200,000 a week to commit his future to the Anfield club.

Arsenal have been locked in negotiations with Mesut Ozil over a new contract but the two parties have not yet managed to come to an agreement as the Gunners are not ready to match the German International's wage demands.

You could argue the governor doesn't have any degree of control over these protests, but each group has a slate of demands, from school aid to pension security to a new contract.

In a letter sent on behalf of some families Wednesday to L.A. Unified Superintendent John Deasy and the school board — and just before the district begins negotiations with the American Federation of Teachers» City of Angels unit over a new contract — Barnes & Thornburg's Kyle Kirwan demanded that the district «implement a comprehensive system» of evaluating teachers that ties «pupil progress» data to teacher evaluations.

Logic would suggest the sector might be brimming over with new appointments and contracts, particularly in clinical trial management and drug safety, as vaccine candidates are fast - tracked to meet the demands of the health crisis.